You can narrow down the results using the filters
-
Evaluation of a codesigned whole of community approach to promote social connection of older adults in ‘Connect Local’
Expand descriptionConnect Local is a new codesigned social prescribing program that aims to support older community members with at least one chronic health condition who may be experiencing or are at risk of loneliness, social isolation and /or depressive symptoms to links them into local social community activities/programs. The aim of the program is to reduce loneliness, social isolation and/or depressive symptoms and improve physical, mental and social wellbeing. Connect Local has been developed through codesign (2021-2022) including local community stakeholders with the aim to develop a program that is fit for purpose, feasible and sustainable. This evaluation includes program effectiveness, health economic and implementation evaluation. Using a Type 1 Hybrid effectiveness-implementation design permits testing of the outcomes of the intervention while gathering information on its implementation. This information will support the rollout and inform sustainability of Connect Local more broadly.
-
Hysteroscopic Morcellation vs Bipolar Resection for Retained Products of Conception (RPOC): A Pilot Randomised Control Trial
Expand descriptionRationale: Retained products of conception (RPOC) is the presence of fetal and/or placental tissue within the uterus post-delivery (preterm or term), miscarriage or termination. It has a prevalence of 0.5-19% and is most commonly seen after second trimester delivery and termination of pregnancy. Most women with RPOC are symptomatic with uterine bleeding, pelvic pain, fevers and/or uterine tenderness, however, some can be initially asymptomatic and have delayed issues such as amenorrhea and infertility from intra-uterine adhesions. For this reason effective treatment for the management of RPOC is important. There are currently no comparative papers assessing medical versus surgical management of retained products of conception. Often patients trial expectant or medical management, but this is unsuccessful in about 20% of cases. The two main surgical options are dilatation and curettage (D&C) or operative hysteroscopy with resectoscopic techniques. The advantage of an operative hysteroscopy over a dilatation and curettage is that it allows for selective resection under direct vision and is therefore beneficial when other methods have failed, there is a significant amount/vascular RPOC, or there are concerns about interruption or damage to surrounding endometrium. Unfortunately, a systematic review by our group, concluded that the current evidence was inadequate to confirm one surgical technique superior to the other. Hysteroscopic morcellation has been increasingly used in management of intra-uterine pathology, however, only one study by Hamerlynck et al has compared it to bipolar resection in the management of RPOC, specifically with the use of the TruClear (Medtronic). The TruClear device is not available in Australia. This pilot aims to assess the feasibility of our study design, and provide data to allow sample size calculation for the larger study. Objectives: The overall objective of the future full study is to compare operative hysteroscopy with MyoSure XL (Hologic, Inc) intrauterine morcellation to bipolar loop resection in the management of RPOC, in terms of both short-term (surgical efficiency and safety) and long-term outcomes (fertility outcomes). The null hypothesis is that there will be no difference in outcomes. However, we need the pilot data prior to plan this final study, hence this proposed pilot. Methodological Approach: An open label, pilot randomised control trial at Mercy Hospital for Women, a tertiary hospital in Melbourne, Australia. Mercy serves as a referral hospital for operative hysteroscopic management of RPOC. Hysteroscopic morcellation has had good outcomes in the resection of intrauterine pathology (such as fibroids and polyps) and has therefore increasingly also been used in women with RPOC. The more traditionally used method is resection with a bipolar resectoscope; therefore, this will be the choice for the control arm.
-
Delineating gastric emptying after major gastro-oesophageal surgery using real time MRI
Expand descriptionBackground:: Optimising gastric conduit emptying post oesophagectomy is key to improving morbidity outcomes in a cohort of patients with increasingly long survivorship. It is thought that peristaltic function and resultant emptying of the gastric conduit improves over time. However, the relationship between peristalsis and conduit emptying has not been precisely delineated, nor has the presumed recovery. Aims:: In this study, we aim to investigate dynamic MRI as a technique to measure gastric conduit peristalsis in the mediastinum. We will use it to quantify the degree of peristalsis in the established gastric conduit and assess its correlation with emptying. We will also use quality of life and adverse symptom questionnaires to look for a relationship between peristalsis and gastrointestinal quality of life. Hypothesis: Dynamic MRI is an accurate way to measure gastric conduit peristalsis and conduit emptying. Peristaltic activity recovers post oesophagectomy and is more effective in narrower conduits. Brief Methods: Post oesophagectomy patients will be recruited greater than 2 years post oesophagectomy. Dynamic MRI will be performed, and questionnaires and demographic data collected Patients greater than 2 years post oesophagectomy and gastric conduit reconstruction will be prospectively recruited. Static and Dynamic MRIs will be performed in the supine position post consumption of a semisolid meal. Speed, length, and amplitude of peristaltic waves will be measured at 4 time points over a 20-minute period. Gastric Motility Index mm2/s (GMI) will be calculated (velocity x amplitude of peristaltic wave). Gastric conduit volumes will be calculated at the start and end of each MRI.
-
Addressing fall risk by treating obstructive sleep apnea in older people
Expand descriptionFalls are a major cause of preventable injury, hospitalisation, morbidity, and mortality in older adults. 1 in 3 people aged 65 years or greater living at home experience a fall annually. Emerging evidence indicates obstructive sleep apnea (OSA), a common sleep breathing disorder (~50%) in older people, may be an independent contributor to fall risk. Balance and gait decline with time awake and can vary across the circadian cycle with specific periods of vulnerability (e.g., transition in posture, standing up and toileting). In addition, the severity of OSA varies significantly from night to night, which may exacerbate gait abnormalities and fall risk in older people. There is currently a lack of robust evidence that OSA treatment reduces fall risk, hence, OSA is currently ignored in falls prevention and reduction strategies. To address this knowledge gap, our internationally recognised team of clinicians and researcher experts in sleep health, fall risk prevention and rehabilitation will build on our successful uncontrolled pilot study and propose to conduct a randomised controlled trial (RCT) to : (1) establish if treatment of OSA with 6 months of CPAP reduces fall risk markers and improves daytime gait quality, (2) provide first in field insight into the temporal relationship between night-to-night variation in OSA with next day gait quality to identify periods of potential increased vulnerability to falls. We hypothesise that 6 months of CPAP treatment will reduce fall risk markers and improve walking and balance.
-
Flinders Albumin In The Home Project
Expand descriptionWe plan to explore the feasibility of providing human albumin infusions in the home setting by community nurses.
-
Individualised Visual field progression observations in glaucoma
Expand descriptionThis 3 year study will observe longitudinal changes to vision in glaucoma using two different visual field testing (perimetry) methods. Glaucoma is a disease of the optic nerve in which peripheral vision is lost. Visual damage in glaucoma is typically measured using a visual field test, which measures the ability to see small white-light targets at various locations spread across the visual field. Current visual field tests use the same test pattern for all people with glaucoma. The primary aim of this study is to observe whether alternate test grids enable earlier detection of progressive damage to the visual field. Clinicians use visual field test information in combination with information from imaging of the eye to make decisions regarding whether people need more treatment. The secondary aim of this study is to combine the information from the visual field tests with information from retinal imaging to improve understanding of how glaucoma progresses.
-
Lutetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic solid tumours.
Expand descriptionThis study is evaluating the safety and properties of 177Lu-RAD204, a PD-L1 antibody joined to a radioactive lutetium isotope. Who is it for? You may be eligible for this study if you are an adult patient with confirmed PD-L1 positive solid tumours including non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple negative breast cancer (TNBC), cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC) and endometrial cancer that is unresectable, progressive and for which standard treatment measures are no longer effective. Study details Participants will undergo a Screening Period of up to 4 weeks, followed by a Phase 0 (Imaging) Period for imaging and receiving a single injection of 177Lu-RAD204. If they are able to tolerate this in the following 2 week period, they will then proceed to a Phase I (Treatment) Period where they will be assigned a dose of 177Lu-RAD204 delivered every 6 weeks for 3 cycles. Blood sampling and imaging studies will be performed to determine how the participant is responding to 177Lu-RAD204. Additional treatment cycles (beyond 3 cycles) will be considered if participant is deemed to receive clinical benefit from 177Lu-RAD204 and approved by study Sponsor. Findings from this study will help determine a recommended dose of 177Lu-RAD204 for future exploration
-
A clinical trial to determine if antibiotics prevent chest infections in patients with brain injuries requiring life support in the intensive care unit
Expand descriptionLower respiratory tract (chest) infections are a common complication in patients placed onto mechanical ventilation (life support) in the intensive care unit (ICU). Patients with brain injuries who require invasive mechanical ventilation may be particularly susceptible to chest infections – the consequence of which may be worsening of their neurological injury. A recent multi-centre randomised clinical trial showed a significant reduction in ventilator associated pneumonia in mechanically ventilated patients after out of hospital cardiac arrest who received prophylactic (preventative) antibiotics starting within 6 hours of cardiac arrest. It is possible that patients with acute brain injuries would also benefit from this strategy as indicated by small pilot studies but it is not known whether this will lead to patient important outcomes such as increased survival with a favourable neurological outcome. This study aims to answer the question, do prophylactic antibiotics reduce the occurrence of lower respiratory tract infections in adults with acute neurological injuries requiring mechanical ventilation. This will then inform the design of a phase 3 trial testing the hypothesis that this treatment regime will increase survival with a favourable outcome at day 180 in these patients.
-
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies
Expand descriptionThis study will be conducted in two parts to assess the safety of AT-0174, how the treatment interacts within the body and to determine the maximum safe dose that may be administered to patients with advanced solid cancers. Who is it for? You may be eligible for this study if you are aged 18 years or older and you have been diagnosed with a solid cancer, including but not limited to: non-small cell lung carcinoma, small cell lung carcinoma, triple-negative breast carcinoma, malignant melanoma, gastric carcinoma/gastroesophageal junction carcinoma/oesophageal cancer, colorectal carcinoma, pancreatic ductal adenocarcinoma, epithelial ovarian carcinoma (fallopian, ovarian, primary peritoneal carcinoma), endometrial carcinoma, thyroid carcinoma (non- medullary) or moderate-high grade astrocytoma (brain cancer). Study details This study will be conducted across two parts. In the first sub-study (Part 1), participants who choose to enrol in this study will be allocated to the next available dosing cohort. The first cohort will be asked to take a daily oral capsule of AT-0174 for 7 days, followed by 3 weeks of no treatment. The second cohort will be asked to take a daily oral capsule of AT-0174 for 14 days, followed of 2 weeks of no treatment. The third cohort will be asked to take a daily oral capsule of AT-0174 for 28 days with no breaks. In the second sub-study (Part 2), participants who choose to enrol in this study will be allocated to the next available dosing cohort. This sub-study will ask all participants to take a daily oral capsule of AT-0174 for 28 days with no breaks. The dose of AT-0174 may increase in amount or frequency (e.g., twice per day) with each successive cohort in Part 2, based on a careful assessment of the safety and tolerability of each dose. All participants will have their vital signs (heart rate, blood pressure, temperature, etc) checked and will provide blood and urine samples for testing. In addition, participants will have their cancer assessed using CT, MRI or CT/PET scans during the study. Participants may continue taking AT-0174 for as long as they and their doctor agree. It is hoped this research will determine the maximum dose of AT-0174 that can be administered safely without causing severe reactions. Once the safest maximum dose of AT-0174 has been determined, a larger trial investigating the efficacy of AT-0174 as a treatment for a greater number of cancer patients may proceed.
-
An innovative care model using continuous glucose monitoring metric data to provide real-time personalised care for children with diabetes.
Expand descriptionCurrently we are not meeting glycaemic targets using standard care models. This provides the opportunity to review models of care to maximise outcomes. The use of continuous glucose monitor (CGM) data to detect changes in glycaemic control provides an opportunity to adapt our model of care to deliver more personalised and targeted care for young people with diabetes. This trial will test a new model of care, aiming to use CGM data to detect early adverse changes in glycaemic control and provide targeted and tailored intervention to those individuals needing more intensive support. Aim: This study aims to investigate if using fortnightly review CGM for early identification of adverse markers in glycaemic control, with implementation of targeted intervention improves glycaemic outcomes and patient reported outcomes in children living with diabetes compared to those receiving care using the current standard model of care. Objectives: 1) To investigate if targeted intervention based on adverse glycaemic control on CGM metrics improves glycaemic control compared to standard models of care 2) To investigate if patient and family reported satisfaction and outcomes are improved with targeted intervention based on CGM metrics 3) To conduct cost-benefit analysis of targeted intervention compared to standard models of care 4) To conduct post study consultation with consumers and health care professionals for feedback on the study and relevant comments on next stages of digital dashboard development Hypothesis: 1. Using fortnightly review of digital CGM upload for early identification of adverse changes in glycaemic control with targeted personalised clinical intervention can improve overall glycaemic control and patient and family satisfaction compared to 3-monthly review at multidisciplinary appointments.